Massachusetts General Hospital
Latest From Massachusetts General Hospital
Private Company Edition: GHO Capital will invest €975m in pharmaceutical and other opportunities in Europe, but Wellington’s $393m fund is focused on drug discovery and development. Also, Avidity raises $100m and Werewolf launches with $56m.
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
Private Company Edition: Venture capital for emerging therapeutics companies in the US and in ex-US regions reached all-time highs in 2018. Also, Alphamab raises $60m Series B, three new VC funds launch and FLX changes its name to RAPT.
Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.